Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine

Int J Clin Pharmacol Ther. 2000 Nov;38(11):540-5. doi: 10.5414/cpp38540.

Abstract

Aim and method: The effects of short-term treatment with lamotrigine (LTG) (100 mg twice daily for one week) on single dose pharmacokinetics of carbamazepine (CBZ, 200 mg) were investigated in a randomized, double-blinded, placebo-controlled cross-over study with 10 healthy volunteers.

Results: Pharmacokinetic parameters for CBZ or for CBZ-10,11-epoxide, the main metabolite of CBZ, were not significantly affected by LTG pretreatment. The mean (+/- SEM) elimination half-life of CBZ was 33.0+/-1.8 h after pretreatment with placebo and 30.1+/-2.0 h after a one-week-pretreatment with LTG (NS). The area under the serum concentration curve to infinity (AUC) of CBZ was 638+/-45 micromol/l after placebo and 624+/-53 micromol/l after LTG (NS). Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.

Conclusion: These data support the earlier findings that LTG does not significantly affect the rate or extent of absorption, or elimination of CBZ.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anticonvulsants / pharmacology*
  • Carbamazepine / pharmacokinetics*
  • Cross-Over Studies
  • Double-Blind Method
  • Drug Interactions
  • Female
  • Humans
  • Lamotrigine
  • Male
  • Triazines / pharmacology*

Substances

  • Anticonvulsants
  • Triazines
  • Carbamazepine
  • Lamotrigine